Net sales were 19,730 million yen (Year-over-Year (YoY) increase of 31.6%), operating income was 6,696 million yen (YoY increase of 57.6%). Pharmaceutical product sales were 19,361 million yen, and shipment volume was 41,596 tons. Overall profit contribution including foreign exchange effects was significant, led by key products such as CZ, V-Bond, and EXE. Full-year FY2026 forecasts are expected to be revised upward to net sales of 26,500 million yen, operating income of 8,700 million yen, and net income of 6,100 million yen. Capital expenditure plans for the Kitakyushu plant and the start-up timing for a new plant were also disclosed.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4971","jir_company_name":"MEC Company Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-11-11","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/11\/4971-20261111-02.pdf","jir_short_summary":"Net sales were 19,730 million yen (Year-over-Year (YoY) increase of 31.6%), operating income was 6,696 million yen (YoY increase of 57.6%). Pharmaceutical product sales were 19,361 million yen, and shipment volume was 41,596 tons. Overall profit contribution including foreign exchange effects was significant, led by key products such as CZ, V-Bond, and EXE. Full-year FY2026 forecasts are expected to be revised upward to net sales of 26,500 million yen, operating income of 8,700 million yen, and net income of 6,100 million yen. Capital expenditure plans for the Kitakyushu plant and the start-up timing for a new plant were also disclosed.","jir_summary":"### Overview of Results\nFor the third quarter of the current fiscal year, consolidated net sales were 19,730 million yen (YoY increase of 31.6%) and operating income was 6,696 million yen (YoY increase of 57.9%). Pharmaceutical product sales reached 19,361 million yen and shipment volume was 41,596 tons, showing solid performance. Considering increased demand for core products such as CZ, V-Bond, and EXE along with foreign exchange effects, the company expects to raise its full-year forecast by the end of the fiscal year.\n\n### Outlook and Capital Investment\nThe full-year forecast for FY2026 is net sales of 26,500 million yen, operating income of 8,700 million yen, and net income of 6,100 million yen, representing an expected increase from the previous forecast. The company disclosed capital expenditure plans including commencement of the second phase of construction at the Kitakyushu plant with operations planned to start in fiscal 2028, and acquisition of land adjacent to the Nagaoka plant. Funding will be sourced from internal funds and borrowings, and the company will balance shareholder returns and growth investment in line with its cash allocation policy.","jir_financial_highlights":"Consolidated Net Sales: 19,730 million yen (YoY increase of 31.6%)\nOperating Income: 6,696 million yen (YoY increase of 57.9%)\nPharmaceutical Product Sales: 19,361 million yen (YoY increase of 33.0%)\nShipment Volume: 41,596 tons (YoY increase of 19.4%)\nForeign Exchange Impact (NTD\/RMB): Unknown (Unknown)\nFull-Year Forecast (FY2026): Net sales 26,500 million yen, Operating income 8,700 million yen, Net income 6,100 million yen (Difference from previously announced figures; expected upward revision)","jir_category":"","jir_hashtags":"#MECCompanyLtd., #Earnings, #SemiconductorMaterials, #CZSeries, #V-BondSeries","jir_key_figures":"Net sales (Q3): 19,730 million yen\nOperating income (Q3): 6,696 million yen\nPharmaceutical product sales: 19,361 million yen","jir_meta_title":"MEC Company Ltd. FY2026 Q3 Earnings Presentation Materials | Net Sales 19,730 million yen \u00b7 Operating Income 6,696 million yen","jir_meta_description":"Analysis of MEC Company Ltd.'s FY2026 Q3 earnings presentation materials. Summary of increases in net sales and operating income, growth in pharmaceutical product sales and shipment volumes, revisions to full-year forecasts, and disclosed capital expenditure plans for the Kitakyushu plant.","jir_og_title":"MEC Company Ltd. | Q3 Earnings Show Net Sales Growth and Full-Year Forecast Upward Revision Expected","jir_og_description":"MEC's Q3 results: net sales 19,730 million yen, operating income 6,696 million yen. Investor highlights include increased demand for key products CZ\/V-Bond\/EXE, capital expenditure plans, and an expected upward revision of the full-year forecast.","jir_og_image_url":"\/assets\/og\/company-financial_summary.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Net Sales Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"FY2025 1Q\\\",\\\"FY2025 2Q\\\",\\\"FY2025 3Q\\\",\\\"FY2025 4Q\\\",\\\"FY2026 1Q\\\",\\\"FY2026 2Q\\\",\\\"FY2026 3Q\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Net Sales\\\",\\\"data\\\":[148? ,...],\\\"borderColor\\\":\\\"#3e95cd\\\",\\\"fill\\\":false}]}}\"}, {\"jir_chart_id\": \"operating_profit_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Operating Income Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"FY2025 1Q\\\",\\\"FY2025 2Q\\\",\\\"FY2025 3Q\\\",\\\"FY2025 4Q\\\",\\\"FY2026 1Q\\\",\\\"FY2026 2Q\\\",\\\"FY2026 3Q\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Operating Income\\\",\\\"data\\\":[0,0,6696,0,0,0,6696],\\\"borderColor\\\":\\\"#3e95cd\\\",\\\"fill\\\":false}]}}\"}, {\"jir_chart_id\": \"segment_revenue_breakdown\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Revenue by Segment\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Japan\\\",\\\"Taiwan\\\",\\\"China\\\",\\\"Europe\\\",\\\"Thailand\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Net Sales\\\",\\\"data\\\":[185? , 795, 1265, 259, 176],\\\"backgroundColor\\\":\\\"#4285f4\\\"}]}}\"}, {\"jir_chart_id\": \"margin_analysis\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Margin Analysis\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"1Q\\\",\\\"2Q\\\",\\\"3Q\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Operating Margin\\\",\\\"data\\\":[32.5,33.9,34.0],\\\"borderColor\\\":\\\"#34a853\\\",\\\"fill\\\":false}]}}\"}, {\"jir_chart_id\": \"guidance_comparison\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Forecast vs Actual Comparison\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"FY2025 3Q\\\",\\\"FY2026 3Q\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Net Sales\\\",\\\"data\\\":[19.7,26.5],\\\"backgroundColor\\\":\\\"#3e95cd\\\"}]}}\"}]","ir_related_company":9582,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-149205","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n